Evercore ISI analyst Liisa Bayko maintained a Buy rating on Editas Medicine (NASDAQ:EDIT) Inc on Wednesday, setting a price target of $60, which is approximately 6.72% below the present share price of $64.32.
Bayko expects Editas Medicine Inc to post earnings per share (EPS) of -$0.81 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Editas Medicine, with an average price target of $59.8.
The analysts price targets range from a high of $80 to a low of $40.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $379 thousand and a net profit of -$55.4 million. The company's market cap is $4.39 billion.
According to TipRanks.com, Evercore ISI analyst Liisa Bayko is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.7% and a 44.69% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.